Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Ear (auricular) vagus nerve stimulation to speed recovery after acute neurocritical illness

Official title: The TAVERN Trial: Transcutaneous Auricular Vagus Enhanced Recovery in the NeuroICU - A Study of Clinical Outcomes and Cost Reduction

Run by Washington University School of Medicine · NCT07219108 · Data updated 2026-11-12

This trial will test whether noninvasive ear (auricular) vagus nerve stimulation helps adults admitted to the NeuroICU have fewer infections, need fewer tracheostomies, and leave the hospital sooner.

More Obesity and Obesity-related Medical Conditions trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment160 (estimated)
SponsorWashington University School of Medicine
Academic / other
Locations1 site (St Louis, Missouri)
StatusRecruiting
StartedSeptember 24, 2025
Main results expectedSeptember 23, 2027
Study endsSeptember 23, 2027
Registry record updatedOctober 7, 2026
Trial IDNCT07219108 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults (≥18 years) admitted to the NeuroICU within 36 hours of an acute medical or neurological event who meet at least one critical-illness predictor (GCS 4–12, NIH Stroke Scale ≥6, ongoing mechanical ventilation, vasopressor support, subarachnoid hemorrhage, intracerebral hemorrhage with >5 mL hematoma, moderate–severe TBI, or refractory status epilepticus) are ideal candidates.

Probably not a fit

Patients with systemic immunosuppression, active cancer therapy, implanted electrical devices (e.g., pacemaker), or sustained bradycardia on admission are excluded and are unlikely to receive benefit from this intervention.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Adults admitted to the NeuroICU within 36 hours of an acute neurological or medical event are randomized to transcutaneous auricular vagus nerve stimulation (taVNS) or sham stimulation. Blood samples for inflammatory markers are collected on admission and serially during the hospital stay while clinicians track infections, need for tracheostomy, vital signs, blood glucose, peri-hematomal edema, and related interventions. Outcomes include rates of hospital-acquired infection, tracheostomy, ICU and hospital length of stay, physiologic measures, inflammatory marker trends, discharge destination, functional scores up to one year, and a health economic cost analysis. No additional clinic visits are required specifically for the research protocol.

Why it matters

Potential benefit: If successful, taVNS could reduce infection rates and prolonged intubation, shorten ICU and hospital stays, and lower overall care costs for neurocritical patients.

How similar studies have gone: Animal studies and some human work with implantable VNS show anti-inflammatory effects, but transcutaneous auricular VNS in acute neurocritical care is relatively novel with limited clinical data to date.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Age ≥18
* Admission to the NeuroICU within 36 hours of onset of an acute medical condition.
* Patient or authorized legal representative should be able to provide consent within 36 hours of ICU arrival
* Presence of at least one predictor of critical illness and/or severe brain / spinal cord injury:

  * Glasgow Coma Scale GCS \>3 \& \<= 12 at admission
  * NIH stroke scale of 6 or greater
  * Requirement for ongoing mechanical ventilation
  * Requirement for ongoing vasopressor support
  * Diagnosis of subarachnoid hemorrhage
  * Diagnosis of intracerebral hemorrhage with hematoma volume \> 5 ml
  * Diagnosis of moderate-severe traumatic brain injury (GCS \>3 \& \<= 12)
  * Refractory Status epilepticus requiring continuous sedative infusions
  * Other brain or spinal cord injury or lesion requiring intensive care

Exclusion Criteria:

* Systemic immunosuppression
* Receiving ongoing cancer therapy
* Implanted electrical device (e.g., pacemaker, stimulator)
* Bradycardia on admission (Sustained bradycardia on arrival with a heart rate \< 50 bpm for \>5 minutes)
* Risk of imminent death or limitation of care (e.g., Glasgow Coma Scale of 3, pupillary dilatation)
* Expected ICU stay of less than 72 hours, as determined by attending physician or ICU fellow
* Pregnancy
* COVID-19

Where it's running

  • Washington University School of Medicine
    St Louis, Missouri, United States
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.